TransFix Vacuum Tubes are now available for in vitro diagnostic (IVD) use in the USA, for immunophenotyping of white blood cells by flow cytometry.
By stabilizing samples with TransFix/EDTA Vacuum Blood Collection Tubes, recovery of lymphocyte subset markers for the HIV panel can be accomplished over a 14-day period following collection. This is particularly important in the routine diagnosis and immune monitoring of HIV patients.
Learn More about this TransFix product.
Partnering with pharmaceutical, biotechnology, and diagnostics companies to out-license our innovative technologies and products supporting life science research, develop companion diagnostics and in-license IVD technologies/products in the areas of cancer, autoimmune diseases, infectious diseases, allergy and cytological/pathological testing.
Tue, 09 Jan 2018 15:24:11 GMT
How do you detect p62 or phospho-p62 using antibodies? Western blotting? Immunohistochemistry? Quantification of biomarkers is essential for medical and diagnostic application. Selective autophagy and Keap1-Nrf2 are already being discussed for their use as a diagnostic as well as other medical applications.
MBL International has developed new sandwich ELISA kits that can semi-quantify total p62 and its phosphorylation level at Ser403 and Ser349. Phospho-p62 ELISA kits are the first kits to quantify these markers by ELISA in the world research market. It is a chance to get a new discovery in the Autophagy area!
CY-7055: CycLex® Total p62 ELISA Kit
CY-7057: CycLex® Phospho-p62 Ser403 ELISA Kit
CY-7056: CycLex® Phospho-p62 Ser349 ELISA Kit
These kits can help you to prepare cell lysate easily including cell lysis buffers. Phosphatase inhibitor solution is also included in the phosho-p62 kits. They can be used for human and mouse samples.
Total p62 and phospho-p62 levels in HeLa cells Read more
Mon, 11 Dec 2017 16:33:12 GMT
Thu, 02 Nov 2017 16:00:00 GMT
May 22nd, 2017: MEDICAL & BIOLOGICAL LABORATORIES Co., Ltd. (MBL) announced that it has entered into a collaboration agreement with the p53 Laboratory, Agency for Science, Technology and Research (A*STAR) in Singapore to establish the novel screening technology which accelerates the drug discovery targeting Protein-Protein Interactions (PPIs).